Studii

Studiile clinice publicate și în curs de desfășurare ale NostraBiome

La NostraBiome, suntem dedicați avansării înțelegerii și tratamentului afecțiunilor medicale complexe prin cercetare clinică riguroasă. Studiile noastre în curs și planificate se concentrează pe rolul esențial al microbiomului în boli precum boala inflamatorie intestinală (IBD) și cancerul.
Aceste studii subliniază angajamentul nostru de a integra informații avansate privind microbiomul în practica clinică, cu scopul final de a îmbunătăți rezultatele și calitatea vieții pacienților.

Introducing a Novel Personalized Microbiome-Based Treatment for Inflammatory Bowel Disease: Results from NostraBiome’s Internal Validation Study

Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, is characterized by chronic gut inflammation driven by microbial dysbiosis and immune dysfunction. Current therapies primarily involve anti-inflammatory and immunomodulatory strategies; however, many patients experience an inadequate response or a gradual loss of efficacy over time. This study evaluates the clinical efficacy of personalized microbiome modulation (PMM)—an AI-driven intervention designed to restore microbial balance and improve key treatment outcomes such as symptom control and remission rates.

Keywords: inflammatory bowel disease; microbiome; gut dysbiosis; personalized medicine; probiotics; biologic therapy; fecal calprotectin; inflammatory markers; AI-driven therapy

CITEȘTE DETALII

Personalized Microbiome Modulation to Improve Clinical Outcomes in Pediatric Inflammatory Bowel Disease: A Multi-Omics and Interventional Approach

Inflammatory bowel disease (IBD) is a complex disorder influenced by genetic, environmental, and microbial factors, with emerging evidence highlighting the gut microbiome’s role in disease pathogenesis. This study investigates the impact of microbiome-targeted interventions in pediatric IBD by integrating multi-omics analysis, including metagenomics, metabolomics, transcriptomics, and clinical biomarkers, to identify microbial dysbiosis patterns and potential therapeutic targets. A cohort of pediatric IBD patients underwent a personalized intervention involving dietary modifications, probiotic supplementation, and selective antibiotic therapy.

Keywords: pediatric inflammatory bowel disease (IBD); gut microbiome; dysbiosis; microbiome-targeted therapy; microbiome modulation; dietary intervention; probiotic supplementation

CITEȘTE DETALII

AI-Guided Multi-Omic Microbiome Modulation Improves Clinical and Inflammatory Outcomes in Refractory IBD: A Real-World Study

Inflammatory bowel disease (IBD) remains difficult to manage in patients who fail multiple therapeutic lines, and growing evidence suggests that alterations in the gut microbiome contribute to persistent symptoms and inflammatory activity. This study evaluated a three-month, AI-guided, multi-omic personalized microbiome modulation program in adults with treatment-refractory IBD. Baseline stool metagenomic sequencing, blood biomarkers, micronutrient panels, and clinical data were integrated through an artificial intelligence platform to generate individualized plans combining dietary adjustments, targeted synbiotics, selective antimicrobials, and micronutrient correction. Clinical outcomes, inflammatory markers, and microbial signatures were reassessed after three months. Across 358 participants, stool frequency decreased substantially, urgency and rectal bleeding resolved in most patients, and over 70% reported a “much improved” overall condition. Inflammatory biomarkers showed marked normalization, with reductions in hs-CRP and fecal calprotectin observed in over 85% of cases.

Keywords: inflammatory bowel disease (IBD); multi-omics; gut microbiome modulation; artificial intelligence–guided therapy; immunometabolism; microbiome–immune interactions; personalized medicine; short-chain fatty acid–producing bacteria

CITEȘTE DETALII